Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

The hope and hype of curing diabetes with stem cells – our take on the Harvard research and more.
Why aren’t there more therapies and devices for pediatric patients? Find out why and what we can do to help.
Can artificial sweeteners contribute to weight gain and worse diabetes control? A remarkable new study on the role of gut bacteria...
We sit down with new JDRF CEO Derek Rapp for his first interview as CEO – find out what he's excited about for JDRF's future!
Twitter Summary: ViaCyte seeks approval from FDA for first human studies of novel encapsulation stem-cell therapy for #t1D On July 17, ViaCyte filed applications with...
Twitter summary: Using a #T2D therapy for #T1D, Lexicon & JDRF partner up for phase 2 trial of SGLT-2/SGLT-1 dual inhibitor drug On July 9, Lexicon announced a...
The Future of Type 1 Diabetes – what challenges and promises lie ahead? Part two of our interview with David Panzirer and Dana Ball.
What's in store for the Bionic Pancreas? diaTribe visits the Camp Joslin clinical trial in 6-11 year olds for an insider look.
How are the bacteria in our gut related to type 2 diabetes and obesity? The fascinating research.
Twitter summary: NIH commits $20 million for outpatient artificial pancreas studies for potential FDA submission – a big step that speaks volumes On July 21, the NIH...
On May 7, the results of the SEARCH for Diabetes in Youth study published in JAMA found a 21% increase in type 1 diabetes and 31% rise in type 2 diabetes in children...
Twitter summary: Due to company misconduct by Andromeda, biotech co. Hyperion terminates development of immune intervention therapy for #T1D On September 8, Hyperion...
On June 5, Xeris Pharmaceuticals announced that the first patient had been dosed in its phase 2 clinical trial , which is testing “mini-dose” glucagon for the treatment...
Twitter Summary: @DpT1D of the #helmsleytrust talks about need 4 philanthropic support in #T1D in inspiring Wired op-ed David Panzirer , a trustee of the Helmsley...
Debates in type 1 diabetes – what is the future of technology and what is a “cure"? Part three of our interview with David Panzirer and Dana Ball.
On September 24, JAMA published a paper on long-term trends in the number of people with diabetes in the United States from 1980 to 2012. The results showed a leveling-...
Advances for type 2 diabetes at The American Diabetes Association 74th Scientific Sessions
Dr. Kowalski was recently named JDRF’s Chief Mission Officer as well as VP of R&D, a major promotion from his previous role as Vice President, Artificial Pancreas...
After the rapid-acting inhaled insulin Afrezza launched this February, we have been very eager to learn more about how this new product impacts patients’ day-to-day...
Plus, their report on the greatest challenges and opportunities in the field.

Pages